Merck’s COVID-19 Antiviral Pill Molnupiravir Just 30% Effective At Preventing Hospitalizations And Deaths, Analysis Finds

The Wall Street Journal (11/26, Hopkins, McKay, Subscription Publication) reported Merck and partner Ridgeback Biotherapeutics said a final analysis of its COVID-19 treatment molnupiravir found the drug to be less effective than previously thought, prompt...